Tangible Impact
Our evaluation demonstrated that the innovative synthetic graft developed by The Electrospinning Company has the potential to generate substantial cost savings for the NHS. By improving surgical outcomes and reducing failure rates, the innovation could drastically lower the overall cost of ophthalmic procedures, making it a more economical and effective alternative to existing graft options. The findings are now being used to support regulatory discussions and to strengthen the case for NICE adoption, helping to pave the way for widespread implementation.
“Working with HTE has been a very positive experience. Updates were provided regularly, and the final model and report were explained extensively and clearly. The report will be provided to NICE to support the case for our product to be adopted as standard treatment.”
— Gianpaolo Bruti, Project Manager, The Electrospinning Company
Assessing the Challenge
The Electrospinning Company developed a novel synthetic material designed for use in ophthalmic surgery. While the innovation showed strong potential to enhance surgical success rates, its cost-effectiveness and impact on patient outcomes needed to be clearly quantified to support regulatory approval and market adoption.
Tailored Approach
We engaged directly with key opinion leaders in ophthalmology, conducting structured interviews to gain a deep understanding of current clinical practices and unmet needs. To quantify the impact of the innovation, we:
- Conducted a literature review and meta-analysis to assess current surgical success and failure rates.
- Built a decision tree model to compare outcomes between standard care and the new graft.
- Simulated the budgetary impact of the innovation across the UK’s addressable market over a five-year period.
- Performed a probabilistic sensitivity analysis to account for uncertainties.
This structured, evidence-based approach provided The Electrospinning Company with robust, data-driven insights to support their regulatory case and drive commercial success.